Table 1a.
All Cases(N = 10) | Mild(N = 2) | Moderate(N = 4) | Severe(N = 4) | |
---|---|---|---|---|
Gender, n (%) | ||||
Male | 1 (10%) | 0 (0%) | 0 (0%) | 1 (25%) |
Female | 9 (90%) | 2 (100%) | 4 (100%) | 3 (75%) |
Age (years) | ||||
Mean ± SD | 41.9 ± 16.64 | 31.5 ± 0.5 | 31 ± 2.55 | 58 ± 15.92 |
Median | 33 | 31.5 | 31.5 | 58.5 |
Min: Max | 27:80 | 31:32 | 27:34 | 35:80 |
Age group, n (%) | ||||
≤ 65 years | 9 (90%) | 2 (100%) | 4 (100%) | 3 (75%) |
> 65 years | 1 (10%) | 0 (0%) | 0 (0%) | 1 (25%) |
Vaccination to disease onset (days) | ||||
Mean ± SD | 194.78 ± 88.54 | 245 ± 57 | 240 ± 77.62 | 101 ± 10.71 |
Median | 170.5 | 245 | 278.5 | 99 |
Min: Max | 89:302 | 188:302 | 107:296 | 89:115 |
Symptom onset to treatment (days) | ||||
Mean ± SD | 5.8 ± 3.31 | 3.5 ± 1.5 | 3.75 ± 1.79 | 9 ± 2.45 |
Median | 5 | 3.5 | 3.5 | 10 |
Min: Max | 2:11 | 2:5 | 2:6 | 5:11 |
*The most severe stage experienced by patient was used as the diagnostic type (mild, moderate, severe).